Disease · MONDO_0015183
short bowel syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. short bowel syndrome. Diseases, record MONDO_0015183. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015183
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 4 of its 22 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs and TTD
- Open Targets
Drugs22
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TEDUGLUTIDE | CHEMBL2104987 | Protein | Approval | EMA Human Drugs and TTD | 23 | 21 | 21 | Drugs and targets |
| SOMATROPIN | CHEMBL1201621 | Protein | Approval | DailyMed | 4 | 3 | 3 | Drugs and targets |
| FISH OIL TRIGLYCERIDES | CHEMBL4297535 | Approval | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| GLUTAMINE | CHEMBL930 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| GLEPAGLUTIDE | CHEMBL4297761 | Protein | Phase 3 | ClinicalTrials.gov and TTD | 8 | 7 | 7 | Drugs and targets |
| FE 203799 | CHEMBL4563522 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 1 | Drugs and targets |
| L-CITRULLINE | CHEMBL444814 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OPIUM | CHEMBL2107914 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| OPIUM, POWDERED | CHEMBL2107915 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| VUROLENATIDE | CHEMBL5095367 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 2 | 2 | Drugs and targets |
1 to 10 of 22
See all 22 drugsTargets6
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GLP1R | Glucagon-like peptide 1 receptor | 2 | Glucagon-like peptide 1 receptor agonist | Phase 2 | https://conductscience.org/library/genes/2740 | Drugs and targets |
| GLP2R | Glucagon-like peptide 2 receptor | 2 | Glucagon-like peptide 2 receptor agonist | Approval | https://conductscience.org/library/genes/9340 | Drugs and targets |
| ANO1 | Anoctamin-1 | 1 | Anoctamin-1 blocker | Phase 2 | https://conductscience.org/library/genes/55107 | Drugs and targets |
| CFTR | Cystic fibrosis transmembrane conductance regulator | 1 | Cystic fibrosis transmembrane conductance regulator inhibitor | Phase 2 | https://conductscience.org/library/genes/1080 | Drugs and targets |
| GCGR | Glucagon receptor | 1 | Glucagon receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/2642 | Drugs and targets |
| GHR | Growth hormone receptor | 1 | Growth hormone receptor agonist | Approval | https://conductscience.org/library/genes/2690 | Drugs and targets |
Trials45
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03690206 | Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS) | Phase 3 | 106 | 2024-10-21 | Short Bowel Syndrome | GLEPAGLUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00930644 | Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS) | Phase 3 | 88 | 2014-12-24 | Short Bowel Syndrome | TEDUGLUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00798967 | Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects | Phase 3 | 86 | 2012-02-01 | Short Bowel Syndrome | TEDUGLUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00081458 | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome | Phase 3 | 84 | 2013-07-15 | Short Bowel Syndrome | TEDUGLUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00172185 | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) | Phase 3 | 65 | 2013-04-23 | Short Bowel Syndrome | TEDUGLUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02954458 | Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS) | Phase 3 | 61 | 2021-10-13 | Short Bowel Syndrome | TEDUGLUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02682381 | Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition | Phase 3 | 59 | 2018-10-16 | Short Bowel Syndrome | TEDUGLUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02949362 | Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study | Phase 3 | 29 | 2021-06-14 | Short Bowel Syndrome | TEDUGLUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04046328 | Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome | Phase 2 | 13 | 2022-07-19 | Short Bowel Syndrome | CHOLESTYRAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT04991311 | The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome | Phase 3 | 12 | 2024-11-22 | Short Bowel Syndrome | GLEPAGLUTIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 45
See all 45 trialsComparisons in its trials28
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| NT,PBO/TED vs TED/TED: serious adverse events | 32 of 51 | 24 of 37 | 88 | NCT00930644 | Trial comparisons |
| Teduglutide vs Placebo: serious adverse events | 15 of 42 | 12 of 43 | 85 | NCT00798967 | Trial comparisons |
| Low Dose ECC Regimen vs High Dose ECC Regimen: deaths from any cause | 0 of 13 | 0 of 13 | 26 | NCT04046328 | Trial comparisons |
| Low Dose ECC Regimen vs High Dose ECC Regimen: serious adverse events | 0 of 13 | 0 of 13 | 26 | NCT04046328 | Trial comparisons |
| Teduglutide vs Placebo: serious adverse events | 0 of 8 | 0 of 8 | 16 | NCT02099084 | Trial comparisons |
| SHP633-306: Teduglutide 0.05 mg/kg vs TED-C14-004: Teduglutide 0.05 mg/kg: Number of Participants Who Were Completely Weaned Off PS at End of Study (EOS) | 1 of 4 | 2 of 7 | 11 | NCT03596164 | Trial comparisons |
SHP633-306: Teduglutide 0.05 mg/kg vs TED-C14-004: Teduglutide 0.05 mg/kg: Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume | 3 of 4 | 5 of 7 | 11 | NCT03596164 | Trial comparisons |
Total Children (Aged: 1 to 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): Number of Participants With Clinically Significant Changes in Vital Signs Reported as Treatment Emergent Adverse Events (TEAEs) | 0 of 8 | 0 of 2 | 10 | NCT02980666 | Trial comparisons |
Total Children (Aged: 1 to 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs) | 0 of 8 | 0 of 2 | 10 | NCT02980666 | Trial comparisons |
| Total Children (Aged: 1 to 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 8 of 8 | 2 of 2 | 10 | NCT02980666 | Trial comparisons |
1 to 10 of 28
See all 28 comparisons in its trialsPapers from its trials36
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015183
GET https://conductscience.org/api/diseases/v1/MONDO_0015183/drugs?page=2